SUBSCRIBE
SUBSCRIBE

NGS-Based RNA Sequencing Market - Quantitative Research by QYResearch Medical

November 11, 2022 | 
17 min read

The global NGS-based RNA sequencing market size is expected to reach USD 11.4 Billion in 2030 and register a revenue CAGR of 20.3% during the forecast period.

The global NGS-based RNA sequencing market size is expected to reach USD 11.4 Billion in 2030 and register a revenue CAGR of 20.3% during the forecast period.

Rising popularity and demand for high throughput sequencing methods, rapid technological progress in the development of Next-Generation Sequencing (NGS) and RNA sequencing technologies, and growing translation of RNA sequencing in clinical diagnostics are key factors driving revenue growth of the global NGS-based RNA sequencing market.

RNA Sequencing (RNA-Seq) makes use of the benefits of Next-Generation Sequencing (NGS) to find and measure the amount of RNA in a biological sample at a specific moment. Researchers can analyze the complete transcriptome using hypothesis-free experimental methods and high throughput sequencing data from NGS without the need for probes. With measurable data, NGS offers a wide dynamic range and sensitivity to effectively find differentially expressed genes. Using NGS, it is possible to locate the transcriptome’s equivalent of the proverbial needle in a haystack. Alternative splicing sites and new isoforms are examples of novel variants that RNA-Seq is capable of detecting and identifying.

These benefits have prompted researchers to quickly adopt RNA-Seq as a generic technique to tackle this complicated landscape. There are now numerous approaches available, ranging from whole transcriptome sequencing to tailored RNA sequencing, and the best methodology to use depends on the particular requirements of the researcher. Metatranscriptomics, viral epidemiology, gene expression investigations, biomarker identification, and other research applications can all benefit from the unparalleled insights that RNA-seq can provide. Major corporations are therefore providing cutting-edge and unique NGS Based RNA Sequencing Platform and data analysis services and kits that are tailored to the requirements of any significant research in these domains, which is driving the revenue growth of this industry.

Inquiry Before Buying@ https://qyresearchmedical.com/submit-inquiry/118235

Furthermore, Increasing funding grants and research programs are being offered by major biotechnology companies manufacturing such sequencing platforms, which is rising demand for NGS-based RNA sequencing in academic research laboratories as well as Contract Research Organizations (CRO), thus contributing significantly to the revenue growth of this market.

For instance, QIAGEN launched a new grant program in 2021 to unlock the potential of RNA-seq for major research projects. Through this program, they invited researchers to apply for their popular QIAGEN RNA-seq Grant. Grants comprised QIAseq RNA-seq and miRNA-seq kits or Genomic Services, with one grant worth USD 20,000 and six grants worth USD 10,000 each. Furthermore, major partnerships and collaborations between key market players are driving revenue growth of the NGS-based RNA sequencing market. For instance, on May 10, 2022, Singular Genomics Systems, Inc., a company that uses cutting-edge Next-Generation Sequencing (NGS) and multiomics technologies to empower researchers and clinicians, announced that it is collaborating with NVIDIA to validate and improve the performance of G4 Sequencing Platform with NVIDIA Clara Parabricks for secondary analysis, including alignment and variant calling with more than 50 tools for germline and somatic workflows. Researchers and medical professionals using Singular’s G4 next-generation instrument will be able to access Clara Parabricks thanks to this partnership, enabling users to run accelerated bioinformatics pipelines for important applications like whole genome sequencing, exome sequencing, RNA Sequencing (RNA-Seq), and targeted gene panels. Customers will have seamless access to this solution via servers installed on-premises that are equipped with NVIDIA GPUs or the Amazon Web Services cloud.

Market Dynamics:
Driver: Rapid technological progress in the development of Next-Generation Sequencing (NGS) and RNA sequencing technologies to drive market revenue growth

Rapid technological progress in the development of Next-Generation Sequencing (NGS) and RNA sequencing technologies is one of the major factors driving the growth of this market. This industry’s revenue growth is being driven by major corporations introducing cutting-edge and distinctive NGS-based RNA sequencing platforms, data analysis services, and kits that are designed to meet the needs of any substantial research in these fields. For instance, on May 23, 2022, NanoString Technologies, Inc., a global leader of life science technologies for discovery and translational research, announced a seamless, cloud-based workflow that improves customers’ spatial data analysis experience when using Illumina NextSeqTM 1000 and NextSeqTM 2000 sequencing systems and the GeoMx® Digital Spatial Profiler. In addition to this, on August 1, 2022, Novogene America has announced the launch of a new single-cell lab based on the Chromium Platform and powered by 10x Genomics®. Single-cell RNA-seq, which takes advantage of state-of-the-art Next GEM technology powered by 10x Genomics®, enables the identification of each individual cell from a pool of cells by partitioning each cell into a distinct microdroplet called Gel Bead-In EMulsion (GEM), labeling each individual cell with a unique cell barcode, and each mRNA transcript with a Unique Molecular Identifier (UMI), which can be detected using bioinformatics analysis.

Related Reports:

Restraint: Limitations of NGS-based RNA sequencing technologies related to inability of detecting low level genomic variants restraining market growth potential

The limitation of commonly used NGS-based RNA sequencing technology related to the inability to detect low-level genomic variations with high precision is one of the primary factors restraining the growth of this market. The low detection of DNA variations by RNA-Seq is attributed to a variety of factors. First of all, since only the coding portions of genes are translated into mRNA, RNA-Seq is unable to identify any of the variations present in noncoding DNA. The detection of structural variants, sequencing of repetitive sections, phasing of alleles, and differentiation of highly similar genomic regions are all hindered by the short read lengths of commonly employed sequencing techniques. These restrictions may play a significant role in the diagnostic gap in individuals with genetic diseases who have undergone entire exome or even genome sequencing as part of routine NGS.

Product Type Insights:

Based on product type, the global NGS-based RNA sequencing market is segmented into sequencing instruments & consumables, sample preparation, data analysis, storage, & management services, and others.

Sample preparation accounted for the largest revenue share in 2021. The pre-sequencing process step’s rising automation and the rising requirement for standardized sample preparation solutions are some of the key factors driving the revenue growth of this segment. The technology of Next-Generation Sequencing (NGS) has become widely accessible to life scientists over the past five years. During this time, techniques for preparing nucleic acids for sequencing and building NGS libraries have also advanced and changed along with sequencing technologies. For instance, construction of an NGS library has now been proven effective for sequencing RNA and DNA from single cells. As a result, major businesses manufacture RNA library preparation kits that enable stranded and fluid procedures for a wide range of RNA-seq applications, including whole-transcriptome sequencing, tumor profiling using degraded inputs, and sequencing of RNA generated from blood. The growing number of RNA sequencing-related research projects involving the creation of RNA libraries is expected to drive the market’s revenue growth.

Data analysis, storage, & management services segment is expected to register a rapid revenue growth rate during the forecast period. Sequencing produces massive amounts of data, and the necessary analysis might be frightening. The majority of the manual operations involved in the Next-Generation Sequencing (NGS) data analysis process are fortunately being removed by the availability of user-friendly analytical tools and services from major biotechnology companies, which makes it simpler for scientists and researchers to quickly extract useful information. The processing of sequencing data is made easier by user-friendly data analysis and storage management tools, allowing scientists to focus more on their study and less on setting up workflows. Some businesses provide NGS software programs to do analysis after the on-instrument data processing is finished and provide the best response time.

Technology Insights:

Based on technology, the global NGS-based RNA sequencing market is segmented into nanopore sequencing, sequencing by synthesis, ion semiconductor sequencing, and others.

The nanopore sequencing segment accounted for the largest revenue share in 2021. Rapid advancements in reading length, accuracy, and throughput have been made possible by nanopore technology for sequencing single-long DNA and RNA molecules, which is a key driver driving the segment’s revenue growth. Long nanopore RNA sequencing reads, in contrast to conventional RNA-Seq approaches, provide accurate quantification and full-length characterization of natural RNA or cDNA without fragmentation or amplification, simplifying processing and obviating possible sources of bias. Along with identifying nucleotide sequences, direct RNA sequencing also makes it possible to identify base alterations. The analysis of Nanopore dRNA/cDNA sequencing experiments depends heavily on the particular experimental conditions and the relevant biological issues. However, due to extensive experimental and bioinformatics methods using such sequencing technology, the majority of analytical workflows include raw database calling (i.e., conversion of the electric current recordings into a sequence), mapping, and fundamental quality control steps, making them useful to fully utilize nanopore long reads for the exploration of genomes, transcriptomes, epigenomes, and epitranscriptomes.

The Ion semiconductor sequencing segment is expected to grow at a steady revenue CAGR during the forecast period. The market’s revenue growth is being significantly impacted by recent advancements and the development of new features in ion semiconductor sequencing based RNA sequencing services. For example, the Ion AmpliSeq Transcriptome Human Gene Expression Kit targets >20,000 RefSeq transcripts using as little as 10 ng RNA input with a quick and FFPE-compatible workflow, and the Ion AmpliSeq Transcriptome service for gene-level expression analysis is ideal for conventional gene expression analysis. As a result, major corporations are developing a variety of user-friendly ion torrent-based RNA sequencing kits as a result, which is driving the segment’s growth. For instance, Life Technologies Corporation announced the launch of the Ion Total RNA-Seq Kit for the Ion Personal Genome Machine (PGMTM) sequencer, a product that offers a quick, inexpensive, and user-friendly substitute to microarrays for the analysis of transcript expression. Many research laboratories can now access RNA-Seq due to the Ion PGM sequencer, giving researchers access to data that is much more precise and comprehensive than what can be obtained for a comparable cost from microarrays.

Application Insights:

Based on application, the global NGS-based RNA sequencing market is segmented into expression profiling analysis, transcriptomic profiling, variant calling & transcriptome epigenetics, and others.

Transcriptomic profiling accounted for the largest revenue share in 2021. RNA Sequencing (RNASeq) has become a potent technique for researching the transcriptome with the introduction of Next Generation Sequencing (NGS), a technology that permits the sequencing of millions of nucleotide fragments concurrently. The analysis of the transcriptome is being revolutionized by RNA Sequencing (RNA-Seq), which is based on NGS. It is giving researchers visibility into previously unnoticed changes occurring in disease states, in response to therapeutics, under various environmental conditions, and across a wide range of other study designs. It is a highly sensitive and accurate tool for measuring expression across the transcriptome. This is rising demand for NGS-based RNA sequencing solutions in major research projects for characterizing and profiling of transcriptome landscape, which is driving the growth of this segment. For instance, NGS-based transcriptome profiling has been used in projects like The Cancer Genome Atlas (TCGA) and ENCyclopedia of the DNA Elements (ENCODE) to characterize the transcriptome of various human cell lines and tumor samples, respectively.

End-User Insights:

Based on end-user, the global NGS-based RNA sequencing market is segmented into academic research institutions, pharmaceutical & biotechnology companies, hospitals & clinics, and others.

Academic research laboratories accounted for the largest revenue share during 2021. Many researchers are adopting NGS Based RNA technologies for research projects related to genomics, transcriptome analysis, and epigenomics. NGS-based RNA sequencing includes library preparation and deep sequencing on the Illumina X Ten, HiSeq 2500, NextSeq, and MiSeq sequencers employing a range of various techniques to satisfy the individual demands of each research project undertaken in many academic research laboratories. Depending on the experimental layout, multiplexing hundreds of samples is conceivable. All sequencing libraries, whether created by NGS or in a lab, undergo a comprehensive Quality Control (QC) process to guarantee the best possible depth and quality of the sequences. This is rising demand for NGS-based RNA sequencing solutions among research institutes, which is driving revenue growth of this segment.

Regional Insights:

Based on regional analysis, the NGS-based RNA sequencing market in North America accounted for the largest revenue share in the global market in 2021 due to increasing partnerships between major companies and government agencies related to transciptome analysis research. Pioneering venture capital entrepreneurs and investors are partnering with major biotechnology companies to create, launch, and grow genomics startups as well as to fund significant research projects in the fields of genomics and transcriptomics, which is driving the growth of this industry in the region. For instance, On March 9, 2022, the Canadian government proposed funding for five research and development initiatives, headed and co-directed by Ontario Genomics, as part of the Genomic Applications Partnership Program (GAPP), which will move genomics out of the lab and provide practical advantages. The goal of Genome Canada’s GAPP program is to provide funding for initiatives that have a distinct and defined partnership between academic institutions and user partners (receptors), in order to encourage the use of genomics-derived solutions to address important industry challenges or opportunities and to benefit Canada’s socioeconomic standing.

Europe is expected to grow at a steady revenue CAGR during the forecast period. Rising partnerships between government and major companies and increase research & development activities and government-funded research projects in the field of transcriptome-based research are rising demand for NGS-based RNA sequencing platforms, which is one of the major factors driving market growth in this region. For instance, The Horizon-2020 initiative, funded by the European Commission, is funding a project on European Advanced Infrastructure for Innovative Genomics and this project offers funding to more than 150 projects to undertake NGS-based experiments.

Competitive Landscape

Competitive landscape of the global NGS-based RNA sequencing market is fragmented with many key players operating on global and regional levels. Key players are engaged in product development and strategic alliances to expand their respective product portfolio and gain a robust footing in the global market. Major players in the market include Oxford Nanopore Technologies plc, Thermo Fisher Scientific Inc., Illumina Inc., PerkinElmer Inc., Eurofins Scientific, Inc., F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., QIAGEN, Novogene Co., Ltd., and BGI Group.

Initiatives taken by market players are driving growth of the market, for instance:

  • On March 1, 2022, Quantabio, a leading producer of robust DNA and RNA amplification reagents for the most demanding molecular testing and life science research applications, today announced the commercial availability of the sparQ RNA-Seq HMR Kit, an ultra-fast RNA Next-Generation Sequencing (NGS) library preparation tool with integrated ribosomal RNA (rRNA) and globin mRNA depletion. With the new kit, researchers can quickly and easily create high-quality stranded transcriptome libraries from tough FFPE or low-input Human, Mouse, and Rat (HMR) materials in five hours.
  • On April 27, 2022, Lexogen, a company that specializes in transcriptomics and Next-Generation Sequencing, announced the availability of the new CORALL RNA-Seq V2 whole transcriptome library prep kit. The previously released patented Displacement/Stop and Ligation methods are built upon by CORALL RNA-Seq V2. With a wide input range and remarkable performance even for low input (down to 1 ng total RNA) and compromised samples, it is a quick and adaptable kit for whole transcriptome sequencing. CORALL library preparation is quicker than traditional WTS RNA-Seq, requiring only 6 steps and 4.5 hours to finish. CORALL is ideal for processing extremely degraded RNA or FFPE material because it doesn’t require RNA fragmentation.

Segments Covered in the Report

This report offers historical data and forecasts revenue growth at a global, regional, and country level and provides an analysis of the market trends in each of the sub-segments from 2019 to 2030. For this study, Reports and Data have segmented the NGS-based RNA sequencing market based on product type, technology, application, end-use, and region:

Inquiry Before Buying@ https://qyresearchmedical.com/submit-inquiry/118235

Product Type Outlook (Revenue, USD Billion; 2019–2030)

  • Sequencing Instruments & Consumables
  • Sample Preparation
  • Data Analysis, Storage, & Management Services
  • Others

Technology Outlook (Revenue, USD Billion; 2019–2030)

  • Nanopore Sequencing
  • Sequencing By Synthesis
  • Ion Semiconductor Sequencing
  • Others

Application Outlook (Revenue, USD Billion; 2019–2030)

  • Expression Profiling Analysis
  • Transcriptomic Profiling
  • Variant Calling & Transcriptome Epigenetics
  • Others

End-Use Outlook (Revenue, USD Billion; 2019–2030)

  • Academic Research Institutions
  • Pharmaceutical & Biotechnology Companies
  • Hospitals & Clinics
  • Others

Regional Outlook (Revenue, USD Billion; 2019–2030)

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Sweden
    • BENELUX
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • South Africa
    • Israel
    • Rest of MEA

Buy quantitative research Report at discounted price - USD 1500 https://qyresearchmedical.com/report/checkout/118235/1500

You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333

Blog: https://www.novaoneadvisor.com/

Blog: https://www.visionresearchreports.com/

About Us

QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover North America, Europe, Latin America, Middle East and Africa, Asia- Pacific.

For Latest Update Follow Us:

URL - http://www.qyresearchmedical.com/

https://www.linkedin.com/company/qyresearch-medical/

https://www.facebook.com/QYResearch-Medical-108186514228917/

https://twitter.com/qyresearchmedi

Precedence Research